- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03270800
Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers (IMX-02)
A Randomized, Double-blind, Adjuvant-controlled Phase 1a/b Study on Safety and Tolerability With Ascending Multiple Doses of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers
A Phase 1, multi-center, randomised, double-blind and adjuvant-controlled study to evaluate the safety, tolerability, and efficacy of IMX101 in H. pylori-negative and H. pylori-infected healthy volunteers.
The study will be conducted in 2 phases. Phase A: Study design contains 6 cohorts, each containing 8 subjects. Three cohorts (24 subjects) will be H. pylori-negative and 3 cohorts will be H. pylori-infected. Subjects fulfilling the inclusion criteria will be assigned to one of 3 sequential dose cohorts with a 3:1 randomisation to IMX101 or to CTA within each cohort.
Phase B: Two cohorts with H. pylori-infected subjects can be expanded up to 20 subjects in each cohort. The decision whether to expand the cohorts will be taken by the Sponsor and the DSMB, as soon as the results of the safety and efficacy analyses are available.
Up to 72 subjects collectively in Phases A & B will be recruited. depending on immunogenicity status.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany
- ClinicalTrial Site
-
Munich, Germany
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- H. pylori-infected subjects: Confirmed H. pylori infection by urea breath test and serology.
H. pylori-negative subjects: Presenting no H. pylori infection by urea breath test and serology.
- Men and women aged ≥18 years and ≤ 50 years.
- Female subjects must either be of non-childbearing potential or use highly effective methods of contraception for at least 1 month prior to Screening and 1 month after end of study participation (see section pregnancy and contraceptives).
- Women with a negative serum test at Screening (V2) and women of childbearing potential additionally with a negative urine pregnancy test at each visit (except V1 and FU V10/V12).
- Have given written informed consent prior to admission to the study in accordance with ICH-GCP and local legislation.
- Ability to comply with the requirements of the study protocol.
Exclusion Criteria:
- History of successful treatment for H. pylori infection.
- Regular use (once a week or more) of diclofenac, other non-steroidal anti-inflammatory drugs (NSAIDs), e.g. acetylsalicylic acid (Aspirin®), or proton pump inhibitor (PPI). Additionally, PPI is used within 2 weeks prior to V1 and V11.
- Use of anticoagulants (i.e. heparin, coumarin derivatives, e.g. Marcumar®).
- Use of antibiotics employed in H. pylori therapy within the month prior to study entry (V1) as well as 1 month prior to each endoscopy (V3 and V9/V11).
- Recent or current (within the last 6 months) systemic corticosteroid use including inhaled corticosteroids. Topical corticosteroid medication is allowed.
- Current or previous gastric ulcer diseases or preneoplastic changes in the stomach mucosa according to medical records or endoscopy findings confirmed by histological assessment at Baseline (V3).
- Current or previous medically significant gastroduodenal disease.
- Preceding cholera immunisation or disease.
- Uncontrolled hypertension or orthostatic hypotension.
- Body mass index (BMI) ≤ 18 or ≥ 30.
- Poorly-controlled type I or type II diabetes mellitus (glycosylated haemoglobin [HbA1c] ≥ 7.5% within the last 6 weeks) and subjects requiring insulin treatment.
- History, evidence or suspicion of tumour burden.
- Epilepsy or seizure disorder.
- Bleeding diathesis.
- Positive viral serology screening result for hepatitis B surface antigen (HBS Ag), antibodies to hepatitis C virus (HCV Ab), or human immunodeficiency virus (HIV) type 1 and 2.
- Known significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalisation.
- A history of active alcohol abuse or drug addiction.
- Administration of a live vaccine within 90 days prior to the first study immunisation (V4) and throughout the study.
- Receipt of blood, blood products or plasma derivatives 30 days prior to study entry (V1).
- Pregnancy or lactation.
- Participation in a clinical study within 30 days prior to admission to the study if investigational or marketed drug were employed. Any disease or condition which in the Investigator's opinion would exclude the subject from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMX101 vaccine as intradermal and sublingual application
IMX101 vaccine will be administered intradermally and sublingually
|
Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
|
Experimental: CTA control as intradermal and sublingual application
CTA mucosal adjuvans will be administered intradermally and sublingually
|
Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of IMX101
Time Frame: 215 days
|
All subjects who received at least one dose of the IMP will be included in the safety analysis by following parameters: -Adverse events: AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). Separate analyses will be conducted using severity, seriousness, and relationship to the IMP. Treatment-emergent adverse events (TEAEs) will be summarised and tabulated according to the primary system organ class and preferred term.
|
215 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of immune Responses
Time Frame: 215 days
|
Humoral and cellular immune Response towards IMX101 and detection of inhibitory antibodies Secondary Endpoint(s):
|
215 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sandra Zivotic, CTC-NORTH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2015-004761-82
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infected Subjects
-
Rabin Medical CenterUnknownHyperthyroidism | Thyroid Cancer Patients | Helicobacter Pylori Infected Patients
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Fu Jen Catholic University HospitalActive, not recruitingHelicobacter PyloriTaiwan
-
Poitiers University HospitalCompleted
-
Shandong UniversityUnknownHelicobacter PyloriChina
-
Hamamatsu UniversityOita UniversityUnknownHelicobacter PyloriJapan
-
Xijing Hospital of Digestive DiseasesRecruiting
-
Fundación de Investigación Biomédica - Hospital...Completed
Clinical Trials on IMX101 vaccine
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
GlaxoSmithKlineCompletedMalaria | Malaria VaccinesGhana, Burkina Faso
-
Sinovac Biotech Co., LtdCompleted
-
University of OxfordMalaria Research and Training Center, Bamako, MaliActive, not recruiting
-
China National Biotec Group Company LimitedPeking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaboratorsCompletedEnterovirus Infections | InfluenzaChina
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico
-
NovartisNovartis VaccinesCompletedJapanese Encephalitis | Rabies | Pre-Exposure ProphylaxisThailand
-
Novartis VaccinesCompleted
-
NovartisNovartis VaccinesCompletedMeningitis | Meningococcal InfectionUnited States, China, Costa Rica, Guatemala, Panama, Peru
-
University of Witwatersrand, South AfricaUnknownMeasles | Hepatitis A | VaricellaSouth Africa